Eyenovia Inc
EYEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$38.59M
Close$
$-12.29
262.6% downside
Current Fair Value
262.6% downsideOvervalued by 262.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $38.59 Million |
|---|---|
| Enterprise Value | $-686,708,038.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.4 |
| Beta | 1 |
| Outstanding Shares | 12,401,910 |
Return
| Return on Equity | -37.39% |
|---|---|
| Return on Assets | -33.69% |
| Return on Invested Capital | -35.26% |
Valuation & Multiples
| P/E Ratio | -1.02 |
|---|---|
| PEG | 0.22 |
| Price to Sales | 0.12 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -0.84 |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -12.98 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 13, 2025
EPS Estimate
$-7.20
Average shareholder expectationRevenue Estimate
$4.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.11%▲ 2.11% |
|---|---|
| Total Invested | $3,526 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About Eyenovia Inc
33 employeesEyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.